Italy’s Menarini gets into obesity with European rights to GLP-1 from China’s Gan & Leenews2026-09-04T10:44:21+00:00September 4th, 2026|Endpoints News|
Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study findsnews2026-08-20T15:12:43+00:00August 20th, 2026|Endpoints News|
Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemianews2026-08-18T11:01:54+00:00August 18th, 2026|Endpoints News|
Eli Lilly files first lawsuits over retatrutide ‘black market’news2026-08-12T16:38:05+00:00August 12th, 2026|Endpoints News|
Lilly once again beats expectations as tirzepatide accounts for 64% of revenuenews2026-08-05T11:21:31+00:00August 5th, 2026|Endpoints News|
Novo vs. Lilly: Q2’s cardiometabolic grudge matchnews2026-08-04T15:00:54+00:00August 4th, 2026|Endpoints News|
FDA offers updated guidance for generics of weight loss blockbustersnews2026-07-28T18:08:40+00:00July 28th, 2026|Endpoints News|
Lilly’s triple agonist heads to regulators after two more Phase 3 obesity winsnews2026-07-23T11:11:18+00:00July 23rd, 2026|Endpoints News|
Exclusive: Obesity biotech Verdiva hires ex-Metsera CMO as crucial readouts nearnews2026-07-23T10:30:33+00:00July 23rd, 2026|Endpoints News|
New CDER appointment elevates longtime GLP-1 reviewernews2026-07-06T17:05:35+00:00July 6th, 2026|Endpoints News|
